A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma
Clinical trial NCT05390528 · UNKNOWN
Trial details
- NCT number
- NCT05390528
- Sponsor
- Shanghai Henlius Biotech
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-20
- Primary completion
- 2023-09-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.